Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Large Growth in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 40,500 shares, a growth of 841.9% from the November 30th total of 4,300 shares. Based on an average daily volume of 171,400 shares, the short-interest ratio is presently 0.2 days.

Inhibitor Therapeutics Stock Down 15.2 %

OTCMKTS INTI opened at $0.07 on Friday. The stock has a market cap of $11.46 million, a price-to-earnings ratio of -6.65 and a beta of -0.61. Inhibitor Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $0.14. The business has a fifty day moving average of $0.08 and a 200-day moving average of $0.08.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.